4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics, Inc. (FDMT) reported that Chief Legal Officer Scott Bizily exercised options for 1,635 shares of common stock on September 16, 2026 at an exercise price of $4.14 per share and sold the same 1,635 shares at $13.65 per share pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026. Following the option exercise, Bizily held 58,066 options directly, and the option award continues to vest monthly from March 6, 2025 through the fourth anniversary of that date.
4D Molecular Therapeutics, Inc. (FDMT) reported that President and Chief Executive Officer David Kirn, who is also a director, sold 58,333 shares of common stock on September 14, 2026 in an open-market or private transaction at a weighted average price of $13.903 per share. The trade was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, with individual sale prices ranging from $13.43 to $14.15 per share, and left him holding 767,486 shares of common stock directly.
4D Molecular Therapeutics, Inc. (FDMT) reports that officer David Kirn has filed a Form 144 to sell up to 58,333 shares of Class A Common Stock through Goldman Sachs & Co. LLC, with an aggregate market value of $802,662.08, based on 55,244,211 shares outstanding of the same class. The shares were acquired from the issuer in a private transaction on December 15, 2020. The filing also lists prior sales of FDMT Class A Common Stock by Kirn over the past three months under a pre-established selling plan intended to comply with Rule 10b5-1(c).
4D Molecular Therapeutics, Inc. (FDMT) reported that its Chief Legal Officer, Scott Bizily, exercised options for 584 shares of common stock on September 1, 2026 at an exercise price of $6.49 per share and sold the same 584 shares at $14.00 per share. The option exercise and related sale were made under a Rule 10b5-1 trading plan adopted on January 13, 2026. Following the exercise, 2,959 option shares remain outstanding from this award, which vests in equal monthly installments over four years starting June 16, 2022.
4D Molecular Therapeutics, Inc. (FDMT) reported that President and Chief Executive Officer David Kirn exercised stock options for 50,000 shares of common stock at an exercise price of $4.14 per share, reducing that option position to 217,500 options remaining. He then sold a total of 69,076 common shares in open-market transactions on August 19, 2026, including 43,149 shares at a weighted average price of $15.3566 (within a range of $14.91–$15.84) and 25,927 shares at a weighted average price of $16.4173 (within a range of $15.97–$16.65). The filing states these trades were made pursuant to a Rule 10b5-1 trading plan adopted on January 9, 2026.
4D Molecular Therapeutics, Inc. (FDMT) reports that David Kirn has filed to sell shares of the company’s Class A Common Stock under Rule 144. The notice covers up to 69,076 shares, with an aggregate market value of $1,157,713.76, to be sold through Goldman Sachs & Co. LLC.
The sales are made pursuant to a Rule 10b5-1(c) selling plan dated 01/09/2026. The company discloses that 55,244,211 shares of Class A Common were outstanding. Prior sales by David Kirn in the past three months include, for example, 114,746 shares on 06/22/2026 for $1,200,851.31.
4D Molecular Therapeutics, Inc. executive Scott Bizily, Chief Legal Officer, reported paired option exercises and stock sales in FDMT. On August 13, 2026 and August 17, 2026, Bizily exercised stock options covering 1,635 shares of common stock on each date at an exercise price of $4.14 per share, converting a total of 3,270 stock option rights into common shares. On each of those dates, he then sold 1,635 shares of common stock in open-market or private transactions at per-share prices of $12.00 and $12.20, respectively. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026. The exercised options relate to an award that vests monthly, with 1/48th of the underlying shares vesting each month starting on March 6, 2025 until fully vested on the fourth anniversary, while Bizily remains a service provider.
4D Molecular Therapeutics (symbol FDMT) reports a planned sale of 6,540 shares of common stock on 08/17/2026 through Morgan Stanley Smith Barney LLC, following an Exercise of Stock Options for cash. The shares are listed on NASDAQ. The filing also lists prior programmed sales under a 10b5-1 trading plan for Scott Bizily over the past three months.
A stockholder of FDMT, working through Morgan Stanley Smith Barney LLC’s Executive Financial Services, filed to sell 1,635 common shares on NASDAQ on 08/13/2026, with the shares to be issued via an exercise of stock options for cash. The filing also lists prior Rule 10b5-1 plan sales by Scott Bizily over the past three months, including 6,566 shares for $91,924.00 on 06/30/2026 and 9,810 shares for $117,720.00 on 06/23/2026.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company developing AAV genetic medicines and remains pre-commercial with no product sales. For the three months ended June 30, 2026, collaboration and license revenue was $3.8 million, and for the six months it totaled $6.8 million, driven largely by its regional partnership with Otsuka for 4D-150 and its Cystic Fibrosis Foundation agreement.
The company recorded a net loss of $72.9 million in the quarter and $141.7 million year-to-date, compared with $54.7 million and $102.6 million in the prior-year periods, and its accumulated deficit reached $858.0 million. Research and development expenses for the first half of 2026 were $133.3 million, reflecting intensive clinical and preclinical activity.
As of June 30, 2026, cash, cash equivalents and marketable securities had a combined fair value of about $430.6 million, and total assets were $492.6 million. Management states these resources are sufficient to fund planned operations for at least one year. During the period, 4D Molecular Therapeutics also put in place a $200.0 million term loan facility with Hercules Capital and drew an initial $20.0 million, adding modest long-term debt to its balance sheet.